Background: In spite of the popularity and effectiveness of the Implanon among family planning clients at University of Nigeria Teaching Hospital (U.N.T.H) Enugu Nigeria, some users discontinued its use for a variety of reasons.
Objective: To determine the Implanon discontinuation rate and reasons for discontinuation among women attending University of Nigeria Teaching Hospital (U.N.T.H) Enugu, Nigeria.
Materials And Methods: This retrospective survey comprised 63 women who had Implanon implant discontinued out of 295 women who had Implanon inserted between 2006 and 2008. The records of patient at the Family Planning Clinic of the hospital were analysed. The main outcome measured was Implanon discontinuation.
Results: Sixty-three (21.4%) of women who had Implanon implant during this period discontinued its use. The discontinuation rate within six months of use was 3.0%, within one year, 8.1% and within two years, 19.3%. Thirty-six (12.2%) discontinued Implanon because of side effects while 27 (9.2%) discontinued because of desire for pregnancy. Fifteen (41.7%) out of the 36 women who discontinued because of side effects had menstrual abnormalities. Headache and dizziness accounts for the majority (38.1%) of non-menstrual reasons for discontinuation. There was no pregnancy recorded. All those who discontinued Implanon within six months ofuse were because of side effects.
Conclusion: The discontinuation of Implanon before its expiration is low once the users are adequately counseled. Implanon is well accepted among our clients but cost affect its wider use.
Download full-text PDF |
Source |
---|
Front Immunol
December 2024
Wuhan Wuchang Hospital, Wuchang Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China.
Introduction: Non-small cell lung cancer (NSCLC) constitutes approximately 80-85% of cancer-related fatalities globally, and direct and indirect comparisons of various therapies for NSCLC are lacking. In this study, we aimed to compare the efficacy and safety of immune checkpoint inhibitors (ICIs) in patients with epidermal growth factor receptor (EGFR)-mutated NSCLC.
Methods: The electronic databases were systematically searched from inception until March 18, 2024.
Background: Multiple sclerosis (MS) is a chronic autoimmune disease damaging the central nervous system. Diminished inflammatory disease activity (DA) as people with MS (pwMS) age motivated randomized clinical trials assessing disease-modifying therapy (DMT) discontinuation in older pwMS given the concern for risks outweighing benefits. This study aims to examine whether peripheral production of Myelin Basic Protein (MBP)-driven cytokine responses mediate the aging-associated decline in MS inflammatory DA.
View Article and Find Full Text PDFArch Esp Urol
December 2024
Department of Urology, Jinggangshan University Affiliated Hospital, 343000 Ji'an, Jiangxi, China.
Background: Neurogenic bladder dysfunction is a common consequence of stroke, and it substantially impacts the quality of life and functional independence of affected individuals. Traditional treatment modalities have limitations in achieving optimal outcomes. This study aims to explore the effects of electroacupuncture treatment on bladder function and neurogenic bladder urodynamic characteristics in stroke patients.
View Article and Find Full Text PDFNat Med
January 2025
Jacobio Pharmaceuticals Co., Ltd., Beijing, China.
Glecirasib (JAB-21822) is a new covalent oral KRAS-G12C inhibitor. This multicenter, single-arm phase 2b study assessed the efficacy and safety of glecirasib administered orally at 800 mg daily in patients with locally advanced or metastatic KRAS-mutated nonsmall-cell lung cancer. The primary endpoint was the objective response rate (ORR) assessed by an independent review committee (IRC).
View Article and Find Full Text PDFJAMA Intern Med
January 2025
Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts.
Importance: Doxycycline postexposure prophylaxis (doxyPEP) has been shown to decrease the incidence of bacterial sexually transmitted infections (STIs) among people assigned male sex at birth in clinical trials, but data from clinical practice are limited.
Objective: To describe early uptake of doxyPEP and evaluate changes in STI incidence following doxyPEP initiation.
Design, Setting, And Participants: This retrospective cohort study of adults (aged ≥18 years) dispensed HIV preexposure prophylaxis (PrEP) at Kaiser Permanente Northern California during November 1, 2022, to December 31, 2023, examined electronic health record data to compare HIV PrEP users dispensed and not dispensed doxyPEP and rates of bacterial STIs before and after starting doxyPEP.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!